Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
49,458
Total Claims
$1.7M
Drug Cost
808
Beneficiaries
$2,128
Cost/Patient
Risk Score Breakdown 26/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
-92%
Opioid rate vs peers
0.2% vs 2.6% avg
+99%
Cost per patient vs peers
$2,128 vs $1,068 avg
+9%
Brand preference vs peers
9.9% vs 9.0% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
0.2%
Opioid Rate
108
Opioid Claims
$1,012
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 4,864 claims · $1.2M
Generic: 44,507 claims · $493K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 1,223 | $195K |
| Dulaglutide | 115 | $99K |
| Pimavanserin Tartrate | 81 | $92K |
| Fluticasone/Umeclidin/Vilanter | 109 | $83K |
| Insulin Glargine,hum.Rec.Anlog | 236 | $74K |
| Dapagliflozin Propanediol | 68 | $63K |
| Empagliflozin | 238 | $58K |
| Tirzepatide | 38 | $51K |
| Vibegron | 365 | $43K |
| Linagliptin | 225 | $39K |
| Mirabegron | 243 | $34K |
| Insulin Glargine/Lixisenatide | 16 | $28K |
| Atorvastatin Calcium | 3,483 | $24K |
| Leuprolide Acetate | 12 | $21K |
| Semaglutide | 18 | $20K |
Prescribing Profile
Patient Profile
75
Avg Age
53%
Female
1.73
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About